Koers Kancera AB (publ) Nasdaq Stockholm
Aandelen
SE0015658570
Biotechnologie & Medisch Onderzoek
Omzet 2023 | 1,03 mln. 96,61K 88,89K | Omzet 2024 * | - | Marktkapitalisatie | 207 mln. 19,34 mln. 17,8 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2023 | -64 mln. -5,97 mln. -5,5 mln. | Nettowinst (verlies) 2024 * | -81 mln. -7,56 mln. -6,96 mln. | EV/omzet 2023 | 358 x |
Nettoliquiditeiten 2023 * | - 0 0 | Nettoliquiditeiten 2024 * | - 0 0 | EV/omzet 2024 * | - |
K/w-verhouding 2023 |
-9,28
x | K/w-verhouding 2024 * |
-2,44
x | Werknemers | - |
Dividendrendement 2023 * |
-
| Dividendrendement 2024 * |
-
| Vrij verhandelbaar | 37,38% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Peter Selin
CEO | Chief Executive Officer | - | 01-03-22 |
Director of Finance/CFO | 75 | - | |
Johan Schultz
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-13 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 63 | 05-05-10 | |
Director/Board Member | 66 | 01-01-16 | |
Håkan Mellstedt
FOU | Founder | 82 | 28-04-10 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+9,42% | 115 mld. | |
+11,84% | 106 mld. | |
-14,15% | 21,84 mld. | |
-1,05% | 21,96 mld. | |
-5,29% | 19,21 mld. | |
-38,29% | 17,71 mld. | |
-4,16% | 18,08 mld. | |
+7,99% | 14,32 mld. | |
+36,24% | 12,42 mld. |